標題: Titlebook: Leading Pharmaceutical Innovation; Trends and Drivers f Oliver Gassmann,Gerrit Reepmeyer,Maximilian Zedtwi Book 20082nd edition Springer-Ve [打印本頁] 作者: TEMPO 時間: 2025-3-21 16:08
書目名稱Leading Pharmaceutical Innovation影響因子(影響力)
作者: sterilization 時間: 2025-3-21 23:33
Oliver Gassmann,Gerrit Reepmeyer,Maximilian ZedtwiThe book is based on the three most important challenges in pharmaceutical innovation: productivity dilemma, new technology trends, globalization and outsourcing.Due to the CTO-roundtable with 14 sele作者: 菊花 時間: 2025-3-22 03:05
http://image.papertrans.cn/l/image/582419.jpg作者: 消瘦 時間: 2025-3-22 05:26 作者: insurgent 時間: 2025-3-22 11:57
Springer-Verlag Berlin Heidelberg 2008作者: largesse 時間: 2025-3-22 12:54
ation and outsourcing.Due to the CTO-roundtable with 14 selePharmaceutical giants have doubled their investments in drug development in the past decade only to see new drug approvals remain constant. This book investigates and highlights a set of proactive strategies aimed at generating sustainable 作者: Subdue 時間: 2025-3-22 20:13
the drug development pipeline, new technologies as enablers for cutting-edge R&D, and new forms of cooperation and internationalization, such as open innovation in the early phases of R&D. Our findings are illustrated by cases from Europe, the US, and Asia.? ?978-3-540-77636-9作者: chapel 時間: 2025-3-22 21:25 作者: iodides 時間: 2025-3-23 04:40
Future Directions and Trends,g design and delivery, the pharmaceutical industry is facing nothing short of a revolution. This final chapter identifies some trends and suggests potential future directions in leading pharmaceutical innovation:作者: 虛構(gòu)的東西 時間: 2025-3-23 07:54 作者: 拱形大橋 時間: 2025-3-23 12:02
The Science and Technology Challenge: How to Find New Drugs,and technologies. While innovation activities of established pharmaceutical companies were traditionally based on organic chemistry, biochemistry and chemical engineering, biotechnology companies have built a reputation in many novel areas, such as cell biology, molecular genetics, protein chemistry and encymology (Whittaker and Bower 1994).作者: formula 時間: 2025-3-23 14:10
Book 20082nd editioninvestigates and highlights a set of proactive strategies aimed at generating sustainable competitive advantage based on value-generating business practices. We focus on three sources of pharmaceutical innovation: new management methods in the drug development pipeline, new technologies as enablers 作者: menopause 時間: 2025-3-23 21:55
The Pipeline Management Challenge: How to Organize Innovation,ceutical companies are required to deliver between two and four new drugs every year in order to maintain or exceed the double-digit growth expectations. Given the high attrition rates in drug development, they have to fill the R&D pipeline with as many new drug candidates as possible.作者: Dysplasia 時間: 2025-3-23 23:05
Management Answers to Pharmaceutical R&D Challenges,up in 2002, and Basilea Pharmaceutica. This is a further source of promising compounds for the company’s product pipeline. Including several research related agreements with other companies, Roche ranks among the industry leaders in terms of licensing. In total, the Roche Group owns 166 patents (Reuters 2002).作者: 逢迎白雪 時間: 2025-3-24 04:17 作者: Aerate 時間: 2025-3-24 07:27 作者: Affection 時間: 2025-3-24 13:18 作者: Neutropenia 時間: 2025-3-24 15:16
The Pipeline Management Challenge: How to Organize Innovation, of pharmaceutical and biotechnology companies target the therapeutic area of oncology which covers all types of cancer related diseases. Cardiovascular, central nervous system and respiratory related diseases are other important therapy areas. Depending on the size of their current business, pharma作者: 消極詞匯 時間: 2025-3-24 21:35
The Internationalization Challenge: Where to Get Access to Innovation,ountries, where high R&D costs can only be recouped by selling the resulting drug to a worldwide market. International trade statistics by the WTO (2002) illustrate the tremendous increase in international business over the past twenty years. For instance, the amount of worldwide merchandise exports作者: 饑荒 時間: 2025-3-25 00:22
Management Answers to Pharmaceutical R&D Challenges,l in-house research organization, the pharmaceuticals division’s R&D network also includes Genentech and Chugai, which function as largely independent research satellites. In addition, Roche has opt-in rights to the programs of external development organizations it has created, such as BioXell, set 作者: Synchronism 時間: 2025-3-25 03:56 作者: 捕鯨魚叉 時間: 2025-3-25 11:04 作者: paltry 時間: 2025-3-25 15:19 作者: Pulmonary-Veins 時間: 2025-3-25 17:52
ulating the activity of the immune system. As a part of this response, the brain and its neural inputs can activate certain immune components either by direct innervation of immune system tissues such as the thymus gland and spleen, or the central nervous system (CNS) can act through neuroendocrine 作者: 難解 時間: 2025-3-25 21:54
association with many pathological entities with different manifestations and outcomes. Primary hypogammaglobulinemia is caused by defects in B-cell number and maturation, reduced survival and activation of B cells, and faulty interaction between B and T cells and is commonly observed in many primar作者: COWER 時間: 2025-3-26 00:11
to consider how the visual medium of the theatre appraised .This book explores how the humoral womb was evoked, enacted, and embodied on the Shakespearean stage by considering the intersection of performance studies and humoral theory.? Galenic naturalism applied the four humors—yellow bile, black 作者: Overthrow 時間: 2025-3-26 04:50
to consider how the visual medium of the theatre appraised .This book explores how the humoral womb was evoked, enacted, and embodied on the Shakespearean stage by considering the intersection of performance studies and humoral theory.? Galenic naturalism applied the four humors—yellow bile, black 作者: ALLAY 時間: 2025-3-26 12:02 作者: Acclaim 時間: 2025-3-26 15:29
eihen kann, ist alt; in anonymer und unverbindlicher Form reicht die Kenntnis über die erworbene Immunit?t weit in die Geschichte hinein. In der vorbakteriologischen Ara hat man nicht anders verfahren k?nnen, als die entsprechenden Beobachtungen zu sammeln und gegebenenfalls auf rein empirischer Bas作者: 設(shè)想 時間: 2025-3-26 20:12 作者: Trypsin 時間: 2025-3-27 00:53 作者: 打算 時間: 2025-3-27 04:14 作者: 組裝 時間: 2025-3-27 07:38
termines the appearance of larger colonies,. and even larger and more hemoglobinized ones appear after 14 days. The first type is currently defined as colony-forming unit-erythroid (CFU-E).; 14 and 8- to 9-day colonies are referred to as burst-forming unit-erythroid (BFU-E). and intermediate BFU-E,.作者: Graphite 時間: 2025-3-27 11:42 作者: PAGAN 時間: 2025-3-27 16:59
ts with a low immunoglobulin serum level at the initial evaluation, defined causes of secondary hypogammaglobulinemias should be extensively ruled out. In particular, B-cell malignancies (mainly chronic lymphocytic leukemia) and plasma cell dyscrasias should be excluded in patients with low immunogl作者: hallow 時間: 2025-3-27 18:02
er Jahren des vorigen Jahrhunderts im Prinzip gel?st; man stellte im Zusammenhang mit der nunmehr bekannten Rolle der pathogenen Bakterien folgerichtigerweise die Frage nach dem Wesen der erworbenen Immunit?t. Die Erw?gungen über die Natur der antiinfekti?sen Schutzkr?fte des Genesenen beginnen mit 作者: Inflamed 時間: 2025-3-28 01:18
er Jahren des vorigen Jahrhunderts im Prinzip gel?st; man stellte im Zusammenhang mit der nunmehr bekannten Rolle der pathogenen Bakterien folgerichtigerweise die Frage nach dem Wesen der erworbenen Immunit?t. Die Erw?gungen über die Natur der antiinfekti?sen Schutzkr?fte des Genesenen beginnen mit 作者: 大廳 時間: 2025-3-28 05:51
